References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2019-4-24-29

medsovet-3111

Research Article

САХАРНЫЙ ДИАБЕТ

DIABETES MELLITUS

Клинические аспекты и перспективы применения ингибиторов ДПП-4

Clinical aspects and prospects of using DPP-4 inhibitors

Бирюкова

Е. В.

Biryukova

E. V.

Бирюкова Елена Валерьевна - доктор медицинских наук, профессор кафедры эндокринологии и диабетологии.

127473, Москва, ул. Делегатская, д. 20, стр. 1

Biryukova Elena Valeryevna - Dr. of Sci. (Med), Professor of the Department of Endocrinology and Diabetology.

127473, Moscow, 20, Delegateskaya St., b. 1

Федеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный медикостоматологический университет имени А.И. Евдокимова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of the Higher Education «Moscow State University of Medicine and Dentistry named after A.I. Yevdokimov» of the Ministry of Healthcare of the Russian FederationRussian Federation

2019

20082019

042429

2019

Бирюкова Е.В.

Biryukova E.V.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/3111

Сахарный диабет 2 типа - тяжелое заболевание, связанное с развитием тяжелых осложнений. Последние успехи в области диабетологии связаны с инкретин-направленной терапией. Обсуждается механизм действия ингибиторов ДПП-4.Представлены результаты клинических исследований эффективности и безопасности гозоглиптина.

Type 2 diabetes mellitus is a serious disease associated with the development of severe complications. Recent advances in diabetology are related to hormone therapy. The mechanism of action of DPP-4 inhibitors is discussed. The results of clinical studies of the efficacy and safety of gosogliptine are presented.

сахарный диабет 2 типасосудистые осложнениясахароснижающая терапияингибиторы ДПП-4гозоглиптин

type 2 diabetes mellitusvascular complicationssugar-reducing therapyDPP-4 inhibitorsgosogliptine

References1

Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск. М., 2019.

Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I.I. Dedov, M.V. Shestakova, A.Yu. Mayorov. 9th issue. М., 2019. (In Russ.)

Schwartz S.S., Epstein S., Corkey B.E. et al. A Unified pathophysiological construct of diabetes and its complications. Trends Endocrinol Metab. 2017;28(9):645-655. doi: 10.1016/j.tem.2017.05.005.

Cantini G., Mannucci E., Luconi1 M. Perspectives in GLP-1 research: new targets, new receptors. Trends in Endocrinology & Metabolism. 2016;27(6):427-438. http//dx.doi.org/10.1016/j.tem.2016.03.017.

Chrysant S.G., Chrysant G.S. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol. 2012;109(11):1681-1685.

Johns E., McKay G., Fisher M. Dipeptidyl peptidase-4 (DPP-4) inhibitors. Br J Cardiol. 2017;24:(1). doi:10.5837/bjc.2017.001.

ADA Standards of Medical Care in Diabetes. Diabetes Care. 2018,41:S1-S156.

Bohannon N. Overview of the gliptin class (Dipeptidyl Peptidase-4 Inhibitors) in clinical practice. Postgraduate Medicine. 2009;121(1):1-6.

Carr R.D. Drug development from the bench to the pharmacy: with special reference to dipep-tidyl peptidase-4 inhibitor development. Diabet Med. 2016;33:718-722. doi: 10.1111/dme.13066.

Physiology of the Gastrointestinal Tract. Edited by H.M. Said. Elsevier Inc. All 2018.

Мкртумян А.М., Бирюкова Е.В. Использование инкретинов в лечении сахарного диабета 2 типа - вчерашняя мечта, близкая к реальности сегодня. Сахарный диабет. 2005;31(2): 34-41.

Mkrtumyan A.M., Biryukova E.V. The use of incretines in the treatment of type 2 diabetes mellitus is a yesterday's dream, close to reality today. Saharnyj diabet. 2005;31(2): 34-41. (In Russ.)

D’Alessio D.A., Vahl T.P. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab. 2004;286:E882-E90.

Yabe D., Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Prog Biophys Mol Biol. 2011;107(2):248-256. doi: 10.1016/j.pbiomolbio.2011.07.010.

Gutniak M., Orskov C., Holst JJ., Ahren B., Efendic S. Antidiabetogenic effect of glucagonlike peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992;326:1316-1322. doi: 10.1056/NEJM199205143262003.

Ahren B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. Diabetes Metab. 2013;39(3):195-201. doi: 10.1016/j.diabet.2013.03.001.

Ahren B. GLP-1 and extra-islet effects. Horm Metab Res. 2004;36(11-12):842-845.

Von Websky K., Reichetzeder C., Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens. 2014;23(1):54-60.

Kim N-H., Taeyang Yu T., Lee D.H. The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors. BioMed Research International. 2014:368703. http//dx.doi.org/10.1155/2014/368703.

Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism. 2011;13:7-18.

Mannucci E., Pala L., Ciani S. et al. Hypergly-caemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005; 48(6): 1168-1172. doi: 10.1007/s00125-005-1749-8.

Da Silva Junior W.S., de Godoy-Matos A.F., Kraemer-Aguiar L.G. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis? BioMed Research International. 2015:816164. http//dx.doi.org/10.1155/2015/816164.

Schwartz S.L. Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010;8:405-18.

Duarte A.I., Candeias E., Correia S.C. et al. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim Biophys Acta. 2013;1832(4):527-541. doi: 10.1016/j.bbadis.2013.01.008.

http//www.remedium.ru/news/detail.php?ID=69136.

Галстян К.О., Недосугова Л.В., Петунина Н.А. и др. Первый отечественный ингибитор ДПП-4 гозоглиптин в сравнении с вилдаглиптином при лечении пациентов с сахарным диабетом 2 типа. Сахарный диабет. 2016;19(1):89-96.

Galstyan K.O., Nedosugova L.V., Petunina N.A., et al. The first domestic inhibitor of DPP-4 gos-ogliptin in comparison with vildagliptin in the treatment of patients with type 2 diabetes mel-litus. Saharnyj diabet.2016;19(1):89-96. (In Russ.)

Aroda V.A., Henry R.R., Han J., Huang W. et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: Meta-analysis and systematic review. Clinical Therapeutics. 2012;34(6):1247-1258.

Shafiee G., Mohajeri-Tehrani M., Pajouhi M., Larijani B. The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord. 2012;11:17. doi: 10.1186/2251-6581-11-17.

The authors declare that there are no conflicts of interest present.